# Polypeptide-based Nanoconjugates as Versatile Therapeutics

**María J. Vicent**

Polymer Therapeutics Lab., Prince Felipe Research Center, Valencia, Spain
mjvicent@cipf.es

Polypeptides are already playing a major role on a number of different relevant areas such as nanomedicine [1]. The physico-chemical parameters of a polypeptide-conjugate, and hence its biological performance, are defined by an intricate interplay of multiple structural factors. This highlights the need for detailed structure-activity relationship studies to develop the hierarchical strategies of polypeptide conjugate design. However, structural complexity also represents a unique opportunity, since small changes at the structural level might endow nanomedicines with outstanding and unexpected biological performance [1].

In our group, we have overcome the main classical limitations for the synthesis of defined polypeptides using precise controlled reactions followed by an adequate characterization yielding to well-defined polypeptidic architectures by NCA polymerization techniques [2]. In addition, post-polymerization techniques allow us the introduction of a variety of functionalities yielding a set of orthogonal reactive attachment sides [1,3]. Using these techniques and following a bottom-up strategy we have been able to obtain star-based polypeptide architectures with the capacity to self-assemble yielding supramolecular nanostructures with interesting properties [4]. This strategy together with an adequate polymer-drug linker design [5] enabled in vitro and in vivo evaluation, revealing a lack of toxicity, an enhanced in vitro cell internalization rate and significantly greater terminal and accumulation half-life in vivo together with a significant lymph node accumulation [4]. These results allow us to envisage these systems as promising nanocarriers for therapeutic or diagnostic applications, especially in anti-cancer treatments including lymph node metastasis and cancer immunotherapy. Proof of Concept for metastatic breast cancer [5] and for immunotherapy design in melanoma will be also shown as well as the use of this self-assembled architectures in applications such as neurodegenerative disorders [6], spinal cord injury [7] or acute kidney injury [8].

## References

[1]   a) Duro-Castano A. et al. (2014) Polymers 6, 515-551; b) Duro-Castaño A. et al. (2015) Biomater. Sci. 3, 1321-1334; c) Melnyk T et al. (2020) Adv Drug Deliv Rev 160: 136-169; d) Zagorodko O. et al. (2017) Macromolecular Bioscience, 17, 1600316-n/a.
[2]   a) Duro-Castano A. et al. (2015) Mol. Pharm, 12, 3639-3649; b) Conejos-Sánchez I. et al. (2013) Polym. Chem, 4, 3182-3186.
[3]   Barz M., et al. (2013) Polym. Chemistry, 4, 2989-2994
[4]   a) Duro-Castaño A. et al. (2017) Adv. Mat. 29(39):  p. 1702888; b) Zagorodko O. et al. (2021) Polym.Chem. d1py00304f.
[5]   a) Arroyo-Crespo, J.J. et al. (2018) Biomaterials, 186, 8-21; b) Arroyo-Crespo, J.J., et al. (2018) Adv. Func. Mat. 28(22): p. 1800931
[6]   a) Duro-Castano A. et al. (2021) Sci. Adv. 7, eabf9180; b) Cuesta CM. et al. (2021) Nanomedicine:NBM 102376
[7]   Giraldo E. et al. (2021) Biomaterials 276, 121052
[8]   Córdoba-David G. et al. (2020) Sci. Reports, 10, 2056.